Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Intranasal Esketamine in Japanese Elderly and Healthy Adults
NCT02857777Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of esketamine in major depressive disorder (MDD) (2 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Plasma Concentration, Area Under the Plasma Concentration-Time Curve From Time Zero to 12 hours and 5 more. Started Aug 2016; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02857777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02857777.